BBIO - BridgeBio Pharma Inc

BBIO - BridgeBio Pharma Inc

https://bridgebio.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BridgeBio Pharma ( NASDAQ:BBIO )

Benzinga • 4 days, 19 hours ago • score: 0.28

PALO ALTO, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 ( ADH1 ) Investor Webinar on Wednesday, September 10th at 8:00 am ET

GlobeNewswire • 1 week, 5 days ago • score: 0.15

PALO ALTO, Calif., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at ...

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

GlobeNewswire • 1 week, 6 days ago • score: 0.20

PALO ALTO, Calif., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism ...

BridgeBio to Participate in September Investor Conferences

GlobeNewswire • 2 weeks, 5 days ago • score: 0.17

PALO ALTO, Calif., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.

52W High

$53.97

52W Low

$21.72

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.26

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-9.40

EV/Revenue (<3 favorable)

47.95

P/S (TTM) (<3 favorable)

43.27

P/B (<3 favorable)

123.68

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.77%

Institutions (25–75% balanced)

101.45%

Shares Outstanding

191,169,000

Float

151,275,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

235,812,000

Gross Profit (TTM)

226,838,000

EPS (TTM)

-4.13

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-1.21%

ROE (TTM) (>15% strong)

-17.90%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

50.00

Momentum

Bearish momentum

Value

1.5662

Previous

1.8144

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025